TMJ Disorders Market Size was valued at USD 0.5 Billion in 2022. The TMJ Disorders market industry is projected to grow from USD 0.53 Billion in 2023 to USD 0.92 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.10% during the forecast period (2023 - 2032).Increased spending in the healthcare industry worldwide and the rising introduction of advanced treatments are the key market drivers incorporating market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The rising demand for minimally invasive treatments drives the market CAGR for TMJ disorders. Traditional approaches, such as surgical interventions, have been associated with higher risks, longer recovery times, and potential complications. Consequently, patients and healthcare providers are exploring less invasive alternatives with comparable efficacy and reduced invasiveness. Technological advancements have facilitated the development of innovative treatment options. The minimally invasive procedures provide targeted relief and symptoms and improve jaw function, thus gaining popularity among patients. The shift towards minimally invasive treatments in the TMJ disorders market will continue as patients seek effective and less burdensome solutions for their conditions.
Digital health technologies, including telemedicine, mobile applications, and wearable devices, offer unique opportunities to improve patient care, remote monitoring, and patient engagement. Telemedicine has gained prominence, particularly during the COVID-19 pandemic, as it enables remote consultations and follow-ups, reducing the need for in-person visits. This approach improves access to care, especially for patients residing in remote areas or facing mobility challenges. Mobile applications and wearable devices also allow patients to track symptoms, monitor jaw movement, and engage in personalized exercise regimens, enhancing self-management and empowering individuals to participate actively in their treatment journey. AI-powered systems can analyze vast amounts of patient data, identify patterns, and assist healthcare providers in making accurate diagnoses and treatment decisions. Such advancements can potentially revolutionize the TMJ disorders market by improving efficiency, reducing costs, and enhancing patient outcomes.
Another prominent trend in the TMJ disorders market is the growing emphasis on personalized medicine and treatment approaches. TMJ disorders present with a wide range of symptoms and underlying causes, necessitating individualized approaches to diagnosis and treatment. Recognizing this, healthcare professionals are increasingly adopting a comprehensive approach that considers the unique characteristics of each patient. Advancements in diagnostic technologies, such as imaging techniques (e.g., MRI, CBCT scans), aid in the accurate assessment of TMJ disorders and guide personalized treatment planning. Furthermore, research focusing on genetic factors, biomarkers, and molecular pathways associated with TMJ disorders has opened avenues for targeted therapies. Healthcare providers can optimize outcomes and enhance patient satisfaction by tailoring treatments to specific patient profiles.
The increasing demand for minimally invasive treatments, emphasis on personalized medicine, and integration of digital health solutions are key trends driving innovation in this field. These trends offer valuable insights for healthcare providers, manufacturers, and researchers, highlighting the need to adapt to evolving patient preferences, leverage technological advancements, and prioritize patient-centered care. By embracing these trends, the healthcare industry can enhance outcomes and improve the quality of life for individuals suffering from TMJ disorders, driving the TMJ Disorders market revenue.
The TMJ Disorders market segmentation, based on type, includes Myofacial pain, internal derangement, and arthritis. The myofacial pain segment dominated the market. It is characterized by localized pain and tenderness in the muscles that control jaw movement. This pain may be triggered by various factors, such as stress, teeth grinding, muscle tension, or trauma. The primary symptoms include jaw pain, muscle stiffness, and difficulty opening or closing the mouth. Treatment options for Myofacial pain include pain medication, muscle relaxants, physical therapy, stress management techniques, and oral appliances like splints or mouthguards.
The TMJ Disorders market segmentation, based on treatment, includes medication, therapies, and surgical treatment. The medication category generated the most income. It encompasses nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and analgesics. These medications help alleviate pain, reduce inflammation, and relax the muscles surrounding the TMJ.
The TMJ Disorders market segmentation, based on end-user, includes hospitals & clinics, ambulatory surgery centers, research, and academic institutes. The ambulatory surgery centers category generated the most income. These facilities offer outpatient surgical procedures, providing a convenient and cost-effective alternative to traditional hospital settings. ASCs have state-of-the-art technology and specialized surgical instruments, allowing for minimally invasive procedures such as arthroscopy and joint lavage. The ASCs segment is experiencing growth due to shorter waiting times, reduced healthcare costs, and improved patient satisfaction.
Figure 1: TMJ Disorders Market by End-User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American TMJ Disorders market will dominate this market due to the region's high prevalence of these disorders. Moreover, well-established healthcare infrastructure, favorable reimbursement policies, and a high level of awareness among healthcare professionals and patients contribute to the market growth in North America. The region also witnesses advancements in TMJ disorder treatments, including surgical and non-surgical interventions, which further propel market expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: TMJ DISORDERS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's TMJ Disorders market accounts for the second-largest market share due to the major prevalence of TMJ disorders, technological advancements in diagnostic procedures, and the presence of key market players. Furthermore, government initiatives to improve dental healthcare and increase investments in research and development activities about TMJ disorders fuel market growth in Europe. Further, the German TMJ Disorders market held the largest market share, and the UK TMJ Disorders market was the rapid-growing market in the European region.
The Asia-Pacific TMJ Disorders Market is expected to grow at the fastest CAGR from 2023 to 2032. It is due to changing lifestyles, increased stress levels, and a growing senior population. Additionally, the increasing disposable income of the people, improving healthcare infrastructure, and rising awareness about TMJ disorders are incorporating the market in the region. Moreover, a large patient pool and the emergence of innovative treatment options are likely to contribute to market expansion in the Asia Pacific. Furthermore, China’s TMJ Disorders market held the largest market share, and the Indian TMJ Disorders market was the rapid-growing market in the Asia-Pacific region.
TMJ Disorders Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the TMJ Disorders market grow even more. Market participants are also undertaking several strategic activities to spread their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The TMJ Disorders industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the TMJ Disorders industry to benefit clients and increase the market sector. The TMJ Disorders industry has offered some of the most significant medical advantages in recent years. Major players in the TMJ Disorders market, including Sun Pharmaceutical Industries Ltd, Abbott Laboratories Inc., Mylan NV, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Bayer International AG, Allergan Inc., Zydus Cadila, Jubilant Life Sciences Limited, Novartis International AG, and others, are attempting to increase market demand by investing in research and development operations.
Johann Rudolf and Alexander Clavel’s Novartis AG, founded in 1996, located in Basel, Switzerland, is a Swiss international pharmaceuticals company ranked as one of the largest companies in the world. It manufactures several drugs, including diclofenac, clozapine, valsartan, cyclosporine, terbinafine, methylphenidate, and many more. Its products include generic drugs, pharmaceutical drugs, vaccines, over-the-counter drugs, contact lenses, diagnostics, etc. In December 2022, Novartis AG released comprehensive findings from the rapid Phase III APPLY-PNH trial. The results determine that, in contrast to anti-C5 therapy, most patients with paroxysmal nocturnal hemoglobinuria (PNH) who received the investigational oral monotherapy iptacopan experienced clinically significant increases in hemoglobin levels.
Allergan PLC, founded in 2013, and located in Dublin, Ireland, is an American Irish pharmaceutical company that acquires, develops, and manufactures drugs and medical devices in medical aesthetics, eye care, nervous system, and gastroenterology. Its products include Botox, Juvederm, linzess, Alphagan, and many more. ALLERGAN announced that the company had received approvals from the U.S. FDA to market JUVÉDERM VOLLURE XC for the correction of balanced to severe facial wrinkles and acne, different folds in adults over the age of 21.
Key Companies in the TMJ Disorders market include
TMJ Disorders Industry Developments
Recently, M.J. Health has launched its TMJ NextGeneration Device offering with U.S. Food and Drug Administration (FDA) approval. It has been proposed to alleviate temporomandibular joint disorder (TMJD) pain.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.5 Billion |
| Market Size 2023 | USD 0.53 Billion |
| Market Size 2032 | USD 0.92 Billion |
| Compound Annual Growth Rate (CAGR) | 7.10% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Sun Pharmaceutical Industries Ltd, Abbott Laboratories, Mylan NV, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Bayer International AG, Allergan Inc., Zydus Cadila, Jubilant Life Sciences Limited, Novartis International AG. |
| Key Market Opportunities | Various medical research laboratories and academic institutes are leading to new and advanced developments. |
| Key Market Dynamics | Increase in adoption of new and advanced treatments and easy availability of medicines. |
TMJ Disorders Market Highlights:
Frequently Asked Questions (FAQ) :
The TMJ Disorders market size was valued at USD 0.5 Billion in 2022.
The market is projected to grow at a CAGR of 7.10% during the forecast period, 2023-2032.
North America had the largest share of the market.
The key players in the market are Sun Pharmaceutical Industries Limited, Abbott Laboratories, Mylan NV, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Bayer AG, Allergan, Zydus Cadila, Jubilant Life Sciences Limited, Novartis International AG.
The Myofacial pain category dominated the market in 2022.
The medication had the largest share in the market.
The ambulatory surgery center had the largest share of the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
